Combining Fluzoparib and Bevacizumab for Ovarian Cancer Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of fluzoparib combined with bevacizumab in patients with platinum-sensitive recurrent ovarian cancer who have previously been treated with PARP inhibitors. The study aims to enroll 42 patients who have experienced a relapse after receiving platinum-based chemotherapy. Participants will receive maintenance therapy with fluzoparib and bevacizumab after achieving remission or partial remission. The trial will evaluate progression-free survival, overall response rate, disease control rate, duration of response, and safety, alongside genetic testing to identify potential biomarkers for treatment response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ovarian cancer patients with histopathological type: low/high grade serous carcinoma, endometrioid carcinoma,had received platinum-based regimens for at least 1-3 lines after primary cytoreductive surgery.
2. The patient had at least one measurable lesion according to the RECIST V1.1 criteria.
3. The time from the last cycle of chemotherapy to relapse/progression should be more than 6 months.
4. ECOG score 0\~1,age 18\~75 years old
5. The serum or urine pregnancy test must be negative within 7 days before enrollment for the women of childbearing age who should agree that contraception must be used during the trial
6. CBC Hb≥90g/L, ANC≥1.5×109/L, PLT≥100×109/L,
7. Serum ALT≤3×UL, AST≤3×ULN#Serum creatinine≤1.5×ULN#

Exclusion Criteria:

1. Had used bevacizumab within 6 months of enrollment
2. Has combined with other malignant tumor which diagnosed within 5 years and/or needed to be treated. The patients had untreated CNS metastases.
3. The patient had Recent intestinal obstruction, gastrointestinal perforation within 3 months, uncontrolled high blood pressure after medication (Systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg), Moderate to severe cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), moderate to severe deep vein thrombosis and moderate to severe pulmonary embolism occurred within 6 months before enrollment. Patient with coagulation dysfunction.
4. Myocardial infarction, severe arrhythmia and NYHA (New York heart association)≥2 for congestive heart failure
5. Activity or uncontrol severe infection

Where it's running

• Chongqing Cancer Hospital
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Principal investigator: Zou Dongling, M.D. — Chongqing University Cancer Hospital
• Study coordinator: Zou Dongling, PH.D.
• Email: cqzl_zdl@163.com
• Phone: +8613657690699

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Trastuzumab plus bevacizumab vs bevacizumab alone as first-line maintenance therapy for ovarian cancer

  This trial tests whether adding trastuzumab to bevacizumab maintenance helps people with epithelial ovarian cancer after initial platinum-based therapy.

  Recruiting at 3 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT07779538

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Raludotatug Deruxtecan with or without Bevacizumab for advanced ovarian, peritoneal, or fallopian tube cancer

  This trial tests whether adding raludotatug deruxtecan (R-DXd) to or without bevacizumab helps people with advanced ovarian cancer that progressed after PARP-inhibitor maintenance.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Fountain Valley, California and 6 other locations · NCT07743164

• Rina-S with or without bevacizumab after platinum therapy for recurrent platinum-sensitive ovarian cancer

  This trial tests whether Rina-S alone or with bevacizumab works better than the investigator’s choice platinum-based chemotherapy (with or without bevacizumab) for patients with recurrent platinum-sensitive ovarian cancer.

  Recruiting at 12 sites Phase 3 Genmab · Duarte, California and 11 other locations · NCT07564141

• Sac-TMT maintenance for people with non-HRD advanced ovarian cancer

  This trial sees if sacituzumab tirumotecan (sac‑TMT), given with or without bevacizumab, can keep cancer from getting worse after surgery and first‑line platinum chemotherapy in people with non‑HRD advanced ovarian cancer.

  Recruiting at 177 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 176 other locations · NCT07318558

• Fluzoparib with bevacizumab or a low‑carb dietary plan versus fluzoparib alone as first‑line maintenance for HRD‑positive and HRD‑negative advanced ovarian cancer

  This trial tests whether adding bevacizumab or a low‑carb dietary plan to fluzoparib helps women with advanced ovarian cancer, with or without HRD, remain free of cancer longer after first‑line treatment.

  Recruiting at 2 sites Phase 3 Tongji Hospital · Wuhan, Hubei and 1 other locations · NCT06954584

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.